Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Market indexes were looking like they might fall into the red this afternoon, a half hour before the closing bell, based on news from the White House that +25% tariffs were being set on our ...